Figure 2From: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximabMedian progression-free survival (PFS) results. Kaplan-Meier curves for median PFS of colorectal cancer patients treated with irinotecan and cetuximab prospectively allocated in the unfavourable (-------) and favourable (———) arm (3 months vs. 8 months, p < 0.0001).Back to article page